期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 104, 期 2, 页码 239-241出版社
WILEY
DOI: 10.1002/cpt.1086
关键词
-
On December 8, 2016, the New England Journal of Medicine published a sounding board on Real World Evidence (RWE)(1) by the US Food and Drug Administration (FDA) leadership. While the value of RWE based on nonrandomized observational studies was appreciated, such as for hypothesis generating, safety, and measuring quality in healthcare delivery, the authors expressed concerns on the quality of data sources and the ability of methodologies to control for confounding. In response, we offer a few considerations regarding these concerns.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据